Multiple sclerosis - natalizumab for the treatment of adults with highly active relapsing-remitting multiple sclerosis: Final appraisal determination
After considering the feedback from consultation, the Appraisal Committee has prepared a Final Appraisal Determination (FAD) on Natalizumab for the treatment of multiple sclerosis and submitted it to the Institute.
The FAD has been sent to the formal consultees for this appraisal who have 15 working days to consider whether they wish to appeal against it. Subject to any appeal by consultees, the FAD may be used as the basis for the Institute's guidance on the use of the appraised technology in the NHS in England and Wales.
Please note that the appeal period for this appraisal will close at 5pm on 16 July 2007.
-
Multiple sclerosis - natalizumab for the treatment of adults with highly active relapsing-remitting multiple sclerosis: Final appraisal determination
03/07/2007
-
Response to consultee, commentator and public comments on the ACD and comments from website consultation
03/07/2007
-
Consultee and commentator comments on the ACD
-
Expert comments on the ACD
Mark Priest, patient expert, nominated by Multiple Sclerosis Trust
Caroline Haynes, patient expert, nominated by Multiple Sclerosis Trust
Merck Serono
Multiple Sclerosis Group, University of Bristol
Department of Health Social Services and Public Safety for Northern Ireland
Oldham PCT
Department of Health
Royal College of Nursing
Royal College of Physicians
Multiple Sclerosis Trust
Association of British Neurologists
Biogen Idec UK - email
Biogen Idec UK
Response to consultee, commentator and public comments on the ACD and comments from website consultation
Multiple sclerosis - natalizumab for the treatment of adults with highly active relapsing-remitting multiple sclerosis: Final appraisal determination
This page was last updated: 30 March 2010